Metabolic Steatotic Liver Disease

Metabolic Steatotic Liver Disease

Current Knowledge, Therapeutic Treatments, and Future Directions

Henry, Linda; Nguyen, Mindie

Elsevier Science & Technology

06/2024

338

Mole

Inglês

9780323996495

15 a 20 dias

Descrição não disponível.
1. Global Epidemiology of NAFLD (now and forecasted)
2. U.S. Epidemiology of NAFLD (now and forecasted). Linda Henry, PhD; Stanford University, USA
3. Economic and patient reported outcome burden (now and forecasted)
4. NAFLD pathogenesis (environmental and genetic)
5. Clinical presentation and natural history.6. Non-liver comorbidities (prevalence and incidence)
7. Screening, diagnosis, and evaluation of patients with NALFD
8. Non-invasive evaluation of liver fibrosis (serum-based)
9. Non-invasive evaluation of liver fibrosis (imaging/elastography-based)
10. General treatment principles
11. Non-surgical treatment of obesity and metabolic disease
12. Endoscopic and surgical treatment of obesity
13. Pharmacologic treatment of hepatic steatosis
14. Overview and comparison of current guidelines (AASLD, EASL, APASL) on NAFLD and MAFLD controversies
15. Special populations: Fatty liver disease in children and adolescent and in the presence of other liver diseases
16. Special populations: Fatty liver disease in patients with chronic hepatitis
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
Fatty Liver; Nonalcoholic Fatty Liver Disease (NAFLD); Nonalcoholic steatohepatitis (NASH); Metabolic associated fatty liver disease (MAFLD); Obesity, Type 2 Diabetes; Diet; Diagnostics; Children; Global